Novel risk factors for atherosclerosis

Mayo Clinic Proceedings

Volumn 75, Issue 4, 2000, Pages 369-380

  Kullo, Iftikhar J ^a   Gau, Gerald T ^a   Jamil Tajik, A ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ATHEROSCLEROSIS; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS; FIBRINOLYSIS; HELICOBACTER PYLORI; HERPES VIRUS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; REVIEW; RISK FACTOR;

EID: 0034072717     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/75.4.369     Document Type: Review

References (160)

1. Heller RF, Chinn S, Pedoe HD, Rose G. How well can we predict coronary heart disease? findings in the United Kingdom Heart Disease Prevention Project. BMJ. 1984;288:1409-1411.
2. Wald NJ, Law M, Watt HC, et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet. 1994;343: 75-79.
3. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation. 1998;97:596-601.
4. Chaturvedi N, McKeigue PM, Marmot MG. Relationship of glucose intolerance to coronary risk in Afro-Caribbeans compared with Europeans. Diabetologia. 1994;37:765-772.
5. Yao C, Wu Z, Wu Y. The changing pattern of cardiovascular diseases in China. World Health Stal Q. 1993;46:113-118.
6. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. / Am Coll Cardiol. 1996;27:517-527.
7. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993;39:1764-1779.
8. Kang SS, Wong PW, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine: a possible risk factor for coronary artery disease. J Clin Invest. 1986;77:1482-1486.
9. Jacobsen DW, Gatautis VJ, Green R, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem. 1994;40:873-881.
10. Chauveau P, Chadefaux B, Coude M, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic urémie patients. Kidney Int Suppl. 1993;41:S72-S77.
11. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993;57:47-53.
12. Berger PB, Jones JD, Oison LJ, et al. Increase in total plasma homocysteine concentration after cardiac transplantation. Mayo ClinProc. 1995;70:125-131.
13. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997;277:1775-1781.
14. Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Seihub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis. 1995;116:147-151.
15. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995:274:1049-1057.
16. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992:268:877-881.
17. Genest JJ Jr, McNamara JR, Upson B, et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb. 1991 ; 11:1129-1136.
18. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotidartery stenosis. N Engl J Med. 1995:332:286-291.
19. van den Berg M, Stehouwer CDA, Bierdrager E, Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vase Biol. 1996; 16:165-171.
20. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation. 1995:92: 2825-2830.
21. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997:337:230-236.
22. Starkebaum G, Harlan JM. Endothelial cell injury due to coppercatalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1986;77:1370-1376.
23. Tsai JC, Wang H, Perrella MA, et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest. 1996;97:146-153.
24. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease: enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vase Biol. 1997:17:2074-2081.
25. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 1986;77:1909-1916.
26. Rodgers GM, Conn MT. Homocysteine. an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990:75:895-901.
27. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest. 1993;91:2873-2879.
28. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J. 1997:11:1157-1168.
29. Celermajer DS, Sorensen K, Ryalls M, et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol. 1993:22:854-858.
30. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endotheliumdependent vasodilation in humans. Circulation. 1997:95:1119-1121.
31. Woo KS. Chook P, Lolin YI, et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 1997:96:2542-2544.
32. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279:359-364.
33. Bostom AG, Shemin D, Lapane KL, et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidne\ Int. 1996:49:147-152.
34. Malinow MR. Duell PB, Hess DL, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med. 1998; 338:1009-1015.
35. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993; 118:956-963.
36. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA. 1987:258:1183-1186.
37. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J. 1987:114:413-419.
38. Cremer P, Nagel D, Mann H, et al. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS), I: risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis. 1997:129:221-230.
39. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC, European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
40. Hamsten A, Iselius L. de Faire U, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet. 1987:2:988-991.
41. Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet. 1987; 1:1452-1455.
42. Folsom A. Fibrinogen and cardiovascular risk in the Atherosclerosis and Risk in Communities (ARIC) study. In: Ernst E, ed. Fibrinogen, A New Cardiovascular Risk Factor. Oxford, England: Blackwell; 1992:128-140.
43. Ernst E, Matrai A, Schmolzl C, Magyarosy I. Dose-effect relationship between smoking and blood rheology. Br J Haematol. 1987:65:485-487.
44. Ernst E, Matrai A. Abstention from chronic cigarette smoking normalizes blood rheology. Atherosclerosis. 1987:64:75-77.
45. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J. 1987;113:1006-1010.
46. Ernst E. The role of fibrinogen as a cardiovascular risk factor. Atherosclerosis. 1993 ; 100:1 -12.
47. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208.
48. Ernst E. Lowering the plasma fibrinogen concentration with drugs. Clin Pharm. 1992;! 1:968-971.
49. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
50. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (Ddimer) and the risk of future myocardial infarction among apparently healthy men. Circulation. 1994;90:2236-2240.
51. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
52. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
53. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG, ECAT Study Group. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation. 1996;94:2057-2063.
54. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
55. Cortellaro M, Cofrancesco E, Boschetti C, et al. Increased fibrin turnover and high PAI-I activity as predictors of ischémie events in atherosclerotic patients: a case-control study. Arterioscler Thromb. 1993;13:1412-1417.
56. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J. 1991; 12: 157-161.
57. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a 7-year follow-up. Circulation. 1993;88:2030-2034.
58. Cimminiello C. Tissue-type plasminogen activator and risk of myocardial infarction [letter]. Lancet. 1993;342:48-49.
59. Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis. Baillieres Clin Haematol. 1995;8:345-363.
60. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985; 313:1557-1563.
61. Meade TW, Chakrabarti R, Haines AP, North WR, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. BMJ. 1979; 1:153-156.
62. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 1993;87:1969-1973.
63. Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA, HEART Study Investigators. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation. 1997;96:442-447.
64. Ridker PM, Vaughan DE, Stampfer MJ, Glynn RJ, Hennekens CH. Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. JAMA. 1994;272:929-933.
65. Fujii S, Sobel BE. Direct effects of gemfibrozil on the fibrinolytic system: diminution of synthesis of plasminogen activator inhibitor type 1. Circulation. 1992;85:1888-1893.
66. Gebara OC, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 1995;91 : 1952-1958.
67. Elwood PC, Renaud S, Sharp DS, Beswick AD, O'Brien JR, Yarnell JW. Ischémie heart disease and platelet aggregation: the Caerphilly Collaborative Heart Disease Study. Circulation. 1991 ; 83:38-44.
68. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N EnglJMed. 1990;322:1549-1554.
69. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation. 1991;84: 613-617.
70. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature. 1993;362:801-809.
71. Hennekens CH, Buring JE. Aspirin in the primary prevention of cardiovascular disease. CardiolClin. 1994; 12:443-450.
72. Blann AD, Lip GY. Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis. 1997; 128:135-138.
73. Kwaan HC, Colwell JA, Cruz S, Suwanwela N, Dobbie JG. Increased platelet aggregation in diabetes mellitus. J Lab Clin Med. 1972;80:236-246.
74. Levine PH. An acute effect of cigarette smoking on platelet function: a possible link between smoking and arterial thrombosis. Circulation. 1973;48:619-623.
75. Beswick AD, Fehily AM, Sharp DS, Renaud S, Giddings J. Long-term diet modification and platelet activity. J Intern Med. 1991;229:511-515.
76. Nelson GJ, Schmidt PC, Corash L. The effect of a salmon diet on blood clotting, platelet aggregation and fatty acids in normal adult men.Lipids. 1991:26:87-96.
77. Meade TW, Vickers MV, Thompson SG, Stirling Y, Haines AP, Miller GJ. Epidemiological characteristics of platelet aggregability. BMJ. 1985;290:428-432.
78. Renaud SC, Beswick AD, Fehily AM, Sharp DS, Elwood PC. Alcohol and platelet aggregation: the Caerphilly Prospective Heart Disease Study. Am J Clin Nutr. 1992;55:1012-1017.
79. Freedman JE, Farhat JH, Loscalzo J, Keaney JF Jr. Alphatocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation. 1996;94:2434-2440.
80. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N EnglJMed. 1999;340:1555-1564.
81. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med. 1997; 126:638-644.
82. Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med. 1997;127:895-903.
83. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997;89:2817-2821.
84. Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G->A20210 gene variant. Ann Intern Med. 1998;129:89-93.
85. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90:1747-1750.
86. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore). 1989;68:366-374.
87. Hamsten A, Norberg R, Bjorkholm M, de Faire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial in-
88. farction: an association with recurrent cardiovascular events. Lancet. 1986;!: 113-116.
89. Kullo IJ, Edwards WD, Schwartz RS. Vulnerable plaque: pathobiology and clinical implications. Ann Intern Med. 1998; 129: 1050-1060.
90. Scanu AM. Structural and functional polymorphism of lipoprotein(a): biological and clinical implications. Clin Chem. 1995;41 : 170-172.
91. Scanu AM. Lipoprotein(a): a genetic risk factor for premature coronary heart disease. JAMA. 1992;267:3326-3329.
92. Moliterno DJ, Jokinen EV, Miserez AR, et al. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vase Biol. 1995; 15:850-855.
93. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA. 1996;276: 544-548.
94. Budde T, Fechtrup C, Bosenberg E, et al. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb. 1994; 14:1730-1736.
95. Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:2025-2033.
96. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996:77:1179-1184.
97. Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Ear J Clin Invest. 1994;24:444-453.
98. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994; 271:999-1003.
99. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993; 270:2195-2199.
100. Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, Abu-Lebdeh HS. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation. 1997;96:1390-1397.
101. Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K, et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation. 1997;95:329-334.
102. Kirn CJ, Ryu WS, Kwak JW, Park CT, Ryoo UH. Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy. Arch Intern Med. 1996:156:500-504.
103. Solymoss BC, Marcil M, Wesolowska E, Gilfix BM, Lesperance J, Campeau L. Relation of coronary artery disease in women < 60 years of age to the combined elevation of serum lipoprotein (a) and total cholesterol to high-density cholesterol ratio. Am J Cardiol. 1993:72:1215-1219.
104. Hajjar KA, Nachman RL. The role of lipoprotein(a) in atherogenesis and thrombosis. Annu Rev Med. 1996;47:423-442.
105. Naruszewicz M, Selinger E, Davignon J. Oxidative modification of lipoprotein(a) and the effect of beta-carotene. Metabolism. 1992;41:1215-1224.
106. Durrington PN. Lipoprotein (a). Baillieres Clin Endocrinol Metab. 1995;9:773-795.
107. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339:303-305.
108. Haider AW, Andreotti F, Thompson GR. Kluft C, Maseri A, Davies GJ. Serum lipoprotein(a) level is related to thrombin generation and spontaneous intermittent coronary occlusion in patients with acute myocardial infarction. Circulation. 1996;94: 2072-2076.
109. Desmarais RL. Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation. 1995;91:1403-1409.
110. Grainger DJ, Kirschenlohr HL, Metcalfe JC. Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993:260:1655-1658.
111. Takami S, Yamashita S, Kihara S, et al. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation. 1998;97: 721-728.
112. Bartens W, Wanner C. Lipoprotein(a): new insights into an atherogenic lipoprotein. Clin Invest. 1994;72:558-567.
113. Kostner GM. Gavish D. Leopold B, Bolzano K, Weintraub MS. Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989;80:1313-1319.
114. Mäher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 1995:274:1771-1774.
115. Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med. 1994; 154:1106-1110.
116. Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM, Brewer HB Jr. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis. 1985;57:293-301.
117. Jones PH, Pownall HJ, Patsch W, et al. Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects.,/ Lipid Res. 1996;37:1298-1308.
118. Beil FU, Terres W, Orgass M. Greten H. Dietary fish oil lowers lipoprotein(a) in primary hypertriglyceridemia [letter]. Atherosclerosis. 1991:90:95-97.
119. Wilson PW. Kannel WB. Should we measure lipoprotein Lp(a)? [editorial]. Arch Intern Med. 1997:157:1161-1162.
120. Austin MA. King MC, Vranizan KM. Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990:82:495-506.
121. Campos H, Genest JJ Jr. Blijlevens E, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992:12:187-195.
122. Coresh J, Kwiterovich PO Jr. Smith HH, Bachorik PS. Association of plasma triglycéride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. ,/ Lipid Res. 1993:34:1687-1697.
123. Austin MA. Breslow JL, Hennekens CH, Buring JE, Willett WC. Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988:260:1917-1921.
124. Griffin BA, Freeman DJ, Tait GW, et al. Role of plasma triglycéride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994; 106: 241-253.
125. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875-881.
126. Stampfer MJ, Krauss RM, Ma J. et al. A prospective study of triglycéride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996:276:882-888.
127. Lamarche B. Tchernof A, Moorjani S, et al. Small, dense lowdensity lipoprotein particles as a predictor of the risk of ischémie heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation. 1997:95:69-75.
128. de Graaf J, Hak-lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arteriosder Thromb. 1991 ; 11:298-306.
129. Camejo G, Hurt-Camejo E, Bondjers G. Effect of proteoglycans on lipoprotein-cell interactions: possible contributions to atherogenesis. Curr Opin Lipidol 1990; 1:431-436.
130. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographie benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation. 1996;94:2146-2153.
131. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS): treatment effects and relation to coronary angiographie progression. Arteriosder Thromb Vase Biol. 1996; 16:697-704.
132. Hodis HN, Mack WJ, Azen SP, et al. Triglycéride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42-49.
133. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis. 1992;95:69-76.
134. Dreon DM, Fernstrom HA, Miller B, Krauss RM. Low-density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men. FASEBJ. 1994;8:121-126.
135. Gaw A. Can the clinical efficacy of the HMG CoA reductase inhibitors be explained solely by their effects on LDL-cholesterol? [letter]. Atherosclerosis. 1996; 125:267-269.
136. Gaw A, Packard CJ, Caslake MJ, et al. Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis. 1994; 108:137-148.
137. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996;312:1061-1065.
138. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Eng! J Med. 1994;331:417-424.
139. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of Creactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996; 144:537-547.
140. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
141. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425-428.
142. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
143. Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost. 1995;73: 374-379.
144. Mori T, Sasaki J, Kawaguchi H, et al. Serum glycoproteins and severity of coronary atherosclerosis. Am Heart J. 1995;129:234-238.
145. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB, European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462-466.
146. Burke AP, Färb A, Mannan P, Kolodgie FD, Virmani R. Creactive protein is expressed in unstable macrophage-rich atherosclerotic plaques [abstract]. Circulation. 1997;96(suppl I):I-492.
147. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82:513-520.
148. Wolbink GJ, Brouwer MC, Buysmann S, ten Berge U, Hack CE. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C reactive protein complexes. JImmunol. 1996;157:473-479.
149. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Alien J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88-92.
150. Bevilacqua MP, Nelson RM, Mannori G, Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med. 1994;45:361-378.
151. Frothingham C. The relation between acute infectious diseases and arterial \esions.ArchInternMed. 1911;8:153-162.
152. Ophüls W. Arteriosclerosis and cardiovascular disease: their relation to infectious diseases. JAMA. 1921;76:700-701.
153. Fabricant CG, Fabricant J, Litrenta MM, Minick CR. Virusinduced atherosclerosis. / Exp Med. 1978; 148:335-340.
154. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430-436.
155. Buja LM. Does atherosclerosis have an infectious etiology? [editorial]. Circulation. 1996;94:872-873.
156. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation. 1997;96:4095-4103.
157. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97:633-636.
158. Gupta S, Camm AJ. Chlamydia pneumoniae and coronary heart disease [editorial]. BMJ. 1997;314:1778-1779.
159. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
160. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, ROXIS Study Group. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. Lancet. 1997;350:404-407.